Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Neoplasms × adagrasib × Clear all

Status

Terminated 2 Active not recruiting 2 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1 Neoplasm Metastasis 1

Interventions

vorasidenib 1 tovorafenib 1 olaparib 1 glucarpidase 1 enzalutamide 1 adagrasib 1 Nivolumab 1 Carboxypeptidases 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05162443 2025-08-26

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Bristol-Myers Squibb

Approved for marketing

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡